الصفحة الرئيسية>>Proteins>> CD Antigens>> CD3>>Pavurutamab

Pavurutamab

رقم الكتالوجGC72443

(ديسمبر 2018) Pavurutamab (AMG-701) هو جزيء محفز خلية T ثنائي التحديد الذي هو مستضدات نضج الخلايا المضادة ل CD3 و (BCMA).

Products are for research use only. Not for human use. We do not sell to patients.

Pavurutamab التركيب الكيميائي

Cas No.: 2250292-39-6

الحجم السعر المخزون الكميّة
1 mg
675٫00
متوفر

Tel:(909) 407-4943 Email: sales@glpbio.com


مراجعات العميل

بناء على آراء العملاء.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents
Pavurutamab (AMG-701) is a bispecific T cell engager molecule that anti-CD3 and anti-B cell maturation antigens (BCMA). Pavurutamab has an extended half-life based on Pacanalotamab . The Fc of Pavurutamab is coupled to molecules to improve pharmacokinetic parameters. Pavurutamab has potential applications in immune regulation and multiple myeloma (MM).

Pavurutamab (0-10000 pM; 48 h) induces CD69+, CD25+ T cell activation and IFNγ, TNFα, IL-2, IL-4, IL-6, IL-10 cytokine secretion[5].

Pavurutamab (0.02, 0.2 and 2 mg/kg; i.v.; single dose on days 3, 8, 13) reduces tumor volume with time and dose dependent manner in mouse xenograft models[5].
Pavurutamab (0.005, 0.05 and 0.5 mg/kg; i.v.; every 5 days for 6 administrations, lasting for 30 days) reduces tumor volume and increases survival with time and dose dependent manner in NOD/SCID mice transplanted with L-363 multiple myeloma (MM) cells[5].

References:
[1]. Sheridan C. Bispecific antibodies poised to deliver wave of cancer therapies. Nat Biotechnol. 2021 Mar;39(3):251-254.
[2]. Goldsmith SR, et al. Bispecific Antibodies for the Treatment of Multiple Myeloma. Curr Hematol Malig Rep. 2022 Dec;17(6):286-297.
[3]. Cho SF, et al. The immunomodulatory drugs lenalidomide and pomalidomide enhance the potency of AMG 701 in multiple myeloma preclinical models. Blood Adv. 2020 Sep 8;4(17):4195-4207.
[4]. Harrison S J, et al. A phase 1 first in human (FIH) study of AMG 701, an anti-B-cell maturation antigen (BCMA) half-life extended (HLE) BiTE®(bispecific T-cell engager) molecule, in relapsed/refractory (RR) multiple myeloma (MM)[J]. Blood, 2020, 136: 28-29.
[5]. Goldstein RL, et al. AMG 701 induces cytotoxicity of multiple myeloma cells and depletes plasma cells in cynomolgus monkeys. Blood Adv. 2020 Sep 8;4(17):4180-4194.

مراجعات

Review for Pavurutamab

Average Rating: 5 ★★★★★ (Based on Reviews and 30 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Pavurutamab

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.